Effector role of neonatal hepatic CD8(+) lymphocytes in epithelial injury and autoimmunity in experimental biliary atresia

University of Cincinnati, Cincinnati, Ohio, United States
Gastroenterology (Impact Factor: 13.93). 07/2007; 133(1):268-77. DOI: 10.1053/j.gastro.2007.04.031
Source: PubMed

ABSTRACT Lymphocytes populate the livers of infants with biliary atresia, but it is unknown whether neonatal lymphocytes regulate pathogenesis of disease. Here, we investigate this question by examining the role of T lymphocytes in the destruction of extrahepatic bile ducts of neonatal mice using an experimental model of biliary atresia.
Inoculation of neonatal mice with rhesus rotavirus followed by multistaining flow cytometry to quantify expression of interferon-gamma by hepatic lymphocytes, and real-time polymerase chain reaction for mRNA expression of pro-inflammatory cytokines. This was followed by determining the consequences of antibody-mediated depletion of lymphocyte subtypes on the development of biliary obstruction, and coculture and cell transfer experiments to investigate the effector role of lymphocyte subtypes on neonatal biliary disease.
Rotavirus infection results in overexpression of interferon-gamma by neonatal hepatic T cells. Among these cells, depletion of CD4(+) cells did not change the course of inflammatory injury and obstruction of neonatal bile ducts. In contrast, loss of CD8(+) cells remarkably suppressed duct injury, prevented luminal obstruction, and restored bile flow. Coculture experiments showed that rotavirus-primed, but not naïve, CD8(+) cells were cytotoxic to cholangiocytes. In adoptive transfer experiments, we found that primed CD8(+) cells preferentially homed to extrahepatic bile ducts of neonatal mice and invaded their epithelial lining.
Primed neonatal CD8(+) cells can activate a pro-inflammatory program, target diseased and healthy duct epithelium, and drive the phenotypic expression of biliary atresia, thus constituting a potential therapeutic target to halt disease progression.

  • [Show abstract] [Hide abstract]
    ABSTRACT: BACKGROUND:: Distinguishing biliary atresia (BA) from other causes of neonatal cholestasis (NC) is challenging. Continuous BreathIDC-Methacetin breath test (MBT, Exalenz Ltd.) is a novel method that determine liver function. Methacetin is metabolized uniquely by the liver and CO2 is measured passively, through a nasal canula in the exhaled breath. AIM:: To assess the ability of MBT to differentiate BA from other causes of NC. METHODS:: MBT was performed in infants with NC prior to any invasive procedure. Percent dose recovered (PDR) peak and time to peak (TTPP) of C recovered were correlated with blood tests results and degree of fibrosis on liver biopsy. RESULTS:: Fifteen infants were enrolled in the study. Eight were eventually diagnosed as BA. MBT showed that infants with NC from various causes reached the PDR peak after 44.5 ± 6.7 minutes, while infants with BA reached the PDR peak value after 54.7 ± 4.3 minutes (p < 0.005). This suggested low CYP1A2 activity in the BA group. The area under the curve (AUC) was 0.95 (95% CI, 0.83-1), sensitivity of 88% and specificity of 100%. CONCLUSIONS:: This pilot study shows that MBT can differentiate between BA and other causes of NC by time to peak of Methacetin metabolism. The results suggest that MBT may be used as part of the diagnostic algorithm in infants with liver disease. Larger scale studies should be conducted to confirm these initial observations.
    Journal of pediatric gastroenterology and nutrition 06/2012; 56(1). DOI:10.1097/MPG.0b013e3182638d29 · 2.87 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Biliary atresia (BA) is a rare disease of unknown etiology and unpredictable outcome, even when there has been timely diagnosis and exemplary surgery. It has been the commonest indication for liver transplantation during childhood for the past 20 years. Hence much clinical and basic research has been directed at elucidating the origin and pathology of BA. This review summarizes the current clinical variations of BA in humans, its occasional appearance in animals and its various manifestations in the laboratory as an experimental model.
    Orphanet Journal of Rare Diseases 08/2013; 8(1):128. DOI:10.1186/1750-1172-8-128 · 3.96 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Biliary atresia (BA) is a neonatal disease that results in obliteration of the biliary tree. The murine model of BA, which mirrors the human disease, is based upon infection of newborn mice with rhesus rotavirus (RRV), leading to an obstructive cholangiopathy. The purpose of this study was to characterize the temporal relationship between viral infection and the induction of this model. BALB/c mice were infected with RRV on day of life (DOL) 0, 3, 5, and 7. Groups were characterized as early-infection (infection by DOL 3) or late-infection (infection after DOL 5). Early RRV infection induced symptoms in 95% of pups with a mortality rate of 80%. In contrast, late infection caused symptoms in only 50% of mice, and 100% of pups survived. The clinical findings correlated with histological analysis of extrahepatic biliary trees, cytokine expression, and viral titers. Primary murine cholangiocytes isolated, cultured, and infected with RRV yielded higher titers of infectious virus in those harvested from DOL 2 versus DOL 9 mice. Less interferon alpha and beta was produced in DOL 2 versus DOL 9 RRV infected primary cholangiocytes. Injection of BALB/c interferon alpha/beta receptor knockout (IFN-αβR(-/-)) pups at DOL 7 showed increased symptoms (79%) and mortality (46%) when compared to late infected wild type mice. In conclusion, the degree of injury sustained by relatively immature cholangiocytes due to more robust RRV replication correlated with more severe clinical manifestations of cholangiopathy and higher mortality. Interferon alpha production by cholangiocytes appears to play a regulatory role. These findings confirm a temporal dependence of RRV infection in murine BA and begin to define a pathophysiologic role of the maturing cholangiocyte.
    PLoS ONE 07/2013; 8(7):e69069. DOI:10.1371/journal.pone.0069069 · 3.53 Impact Factor